Novartis | NOVN - Capital Ordinário





Capital Ordinário Alterar Data
AbbVie USD 1.77B 1.75B 2025-06
Alcon AG USD 487.4M 0 2026-03
Almirall EUR 214.79M 0 2025-12
Amgen USD 540M 1000K 2026-03
AstraZeneca USD 1.55B 73K 2026-03
Autolus Therapeutics Ltd USD 266.14M 0 2025-12
Bayer EUR 982.42M 0 2025-12
Biogen USD 146.7M 200K 2025-09
Bristol-Myers Squibb USD 2.04B 1.74B 2025-09
Eli Lilly USD 943.5M 3.33M 2026-03
Fresenius EUR 563.24M 0 2025-12
Fresenius Medical Care EUR 270.09M 9.2M 2026-03
Genmab DKK 61.62M 52K 2025-12
Gilead Sciences USD 1.24B 1000K 2026-03
GlaxoSmithKline GBP 4.05B 20.6M 2026-03
GRIFOLS EUR 680.58M 0 2026-03
Hikma Pharmaceutical USD 221.89M 181.89M 2025-12
J&J USD 2.41B 1.74M 2025-12
Lakefront Biotherapeutics EUR 65.9M 0 2026-03
Lonza CHF 68.64M 0 2025-12
Merck EUR 434.78M 0 2026-03
Merck USD 2.47B 12.72M 2025-12
Novartis USD 1.91B 60K 2026-03
Novartis USD 1.91B 10.64M 2025-12
Novo Nordisk DKK 4.44B 0 2025-12
Orion EUR 140.87M 173K 2026-03
Pfizer USD 5.7B 13M 2026-03
Philips EUR 952.02M 729K 2026-03
Recordati EUR 203.43M 928K 2026-03
Regeneron Pharmaceuticals USD 105M 300K 2026-03
Roche Holding CHF 795.62M 699.54K 2025-12
Sanofi EUR 1.21B 8.25M 2026-03
UCB EUR 190.36M 365.15K 2025-12